Experienced in Hemolytic Anemia

Dr. Susumu Inoue

Pediatric Hematology Oncology
1 Hurley Plz, 3a-wb, 
Flint, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Hemolytic Anemia
1 Hurley Plz, 3a-wb, 
Flint, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susumu Inoue is a Pediatric Hematologist Oncology provider in Flint, Michigan. Dr. Inoue is rated as an Experienced provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Hemolytic Anemia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Priority Health
  • HMO
  • POS

Locations

1 Hurley Plz, 3a-wb, Flint, MI 48503

Additional Areas of Focus

Dr. Inoue has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Recruiting
Publish Date: April 16, 2025
Intervention Type: Other
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Other
Key Adverse Events After Childhood Cancer
Key Adverse Events After Childhood Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Other
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Enrollment Status: Completed
Publish Date: July 19, 2018
Intervention Type: Other
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
Enrollment Status: Completed
Publish Date: July 16, 2018
Intervention Type: Other
View 12 Less Clinical Trials

9 Total Publications

Rothmund-Thomson syndrome (RTS) with osteosarcoma due to RECQL4 mutation.
Rothmund-Thomson syndrome (RTS) with osteosarcoma due to RECQL4 mutation.
Journal: BMJ case reports
Published: January 26, 2018
Similar Doctors
Distinguished in Hemolytic Anemia
Dr. Ahmar U. Zaidi
Pediatric Hematology Oncology
Distinguished in Hemolytic Anemia
Dr. Ahmar U. Zaidi
Pediatric Hematology Oncology
Detroit, MI 
 (56.9 miles away)
313-745-5515
Languages Spoken:
English
See accepted insurances

Ahmar Zaidi is a Pediatric Hematologist Oncology provider in Detroit, Michigan. Dr. Zaidi is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Phosphoglycerate Kinase Deficiency, Sickle Cell Disease, Hemoglobinopathy, and Congenital Hemolytic Anemia.

Distinguished in Hemolytic Anemia
Dr. Michael U. Callaghan
Pediatric Hematology Oncology
Distinguished in Hemolytic Anemia
Dr. Michael U. Callaghan
Pediatric Hematology Oncology
3901 Beaubien St, 
Detroit, MI 
 (56.8 miles away)
313-745-5515
Languages Spoken:
English
See accepted insurances

Michael Callaghan is a Pediatric Hematologist Oncology provider in Detroit, Michigan. Dr. Callaghan is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Hemophilia A, Blood Clots, Sickle Cell Disease, Evans Syndrome, and Splenectomy.

Advanced in Hemolytic Anemia
Dr. Kelly J. Walkovich
Pediatric Hematology Oncology
Advanced in Hemolytic Anemia
Dr. Kelly J. Walkovich
Pediatric Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (50.9 miles away)
Languages Spoken:
English
See accepted insurances

Kelly Walkovich is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Walkovich is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Infantile Neutropenia, Non-Langerhans-Cell Histiocytosis, and Aplastic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Inoue's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile